- Home
- YHGJ vs MIRA Comparison
YHGJ vs MIRA Comparison
Compare YHGJ & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YHGJ
- MIRA
- Stock Information
- Founded
- YHGJ 1975
- MIRA 2020
- Country
- YHGJ United States
- MIRA United States
- Employees
- YHGJ N/A
- MIRA N/A
- Industry
- YHGJ Specialty Chemicals
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- YHGJ Industrials
- MIRA Health Care
- Exchange
- YHGJ Nasdaq
- MIRA Nasdaq
- Market Cap
- YHGJ 25.9M
- MIRA 25.2M
- IPO Year
- YHGJ 1997
- MIRA 2023
- Fundamental
- Price
- YHGJ $5.42
- MIRA $1.32
- Analyst Decision
- YHGJ
- MIRA
- Analyst Count
- YHGJ 0
- MIRA 0
- Target Price
- YHGJ N/A
- MIRA N/A
- AVG Volume (30 Days)
- YHGJ 401.2K
- MIRA 552.9K
- Earning Date
- YHGJ 11-07-2025
- MIRA 11-11-2025
- Dividend Yield
- YHGJ N/A
- MIRA N/A
- EPS Growth
- YHGJ N/A
- MIRA N/A
- EPS
- YHGJ N/A
- MIRA N/A
- Revenue
- YHGJ $18,964,000.00
- MIRA N/A
- Revenue This Year
- YHGJ N/A
- MIRA N/A
- Revenue Next Year
- YHGJ N/A
- MIRA N/A
- P/E Ratio
- YHGJ N/A
- MIRA N/A
- Revenue Growth
- YHGJ 5.70
- MIRA N/A
- 52 Week Low
- YHGJ $4.35
- MIRA $0.73
- 52 Week High
- YHGJ $12.70
- MIRA $2.56
- Technical
- Relative Strength Index (RSI)
- YHGJ 58.82
- MIRA 46.42
- Support Level
- YHGJ $5.31
- MIRA $1.25
- Resistance Level
- YHGJ $10.29
- MIRA $1.37
- Average True Range (ATR)
- YHGJ 0.95
- MIRA 0.05
- MACD
- YHGJ 0.07
- MIRA 0.00
- Stochastic Oscillator
- YHGJ 50.14
- MIRA 46.23
About YHGJ Yunhong Green CTI Ltd.
Yunhong Green CTI Ltd manufactures and marketers of foil balloons and produces laminated and printed films for commercial uses. The company also distributes balloon-inspired and other gift items, and continues development of compostable material solutions, and markets its products throughout the United States and in several other countries.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.